Decoy Therapeutics Inc. - Common Stock, $0.0001 par value per share (DCOY)
CUSIP: 79400X503
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Shares outstanding
- 7,157,222
- Total 13F shares
- 79,250
- Share change
- +78,713
- Total reported value
- $51,429
- Price per share
- $0.65
- Number of holders
- 9
- Value change
- +$49,570
- Number of buys
- 7
- Number of sells
- 1
Quarterly Holders Quick Answers
What is CUSIP 79400X503?
CUSIP 79400X503 identifies DCOY - Decoy Therapeutics Inc. - Common Stock, $0.0001 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 79400X503:
Top shareholders of DCOY - Decoy Therapeutics Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| CVI Investments, Inc. |
13D/G
|
— |
9.9%
|
708,565
|
$885,706 | +$432,582 | 31 Dec 2025 | |
| INTRACOASTAL CAPITAL, LLC |
13D/G
|
Mitchell P. Kopin |
5%
|
187,295
|
$711,721 | $0 | 12 Nov 2025 | |
| Frederick Pierce II |
3/4/5
|
Chief Executive Office |
0.23%
|
16,666
|
$65,330 | — | 12 Nov 2025 | |
| Mark J. Rosenblum |
3/4/5
|
Exec VP Finance, CFO |
0.28%
|
20,177
|
$16,141 | +$16,000 | 20 Nov 2025 | |
| Arnold C. Hanish |
3/4/5
|
Director |
0.07%
|
5,000
|
$3,198 | +$3,723 | 30 Dec 2025 | |
| Advisory Services Network, LLC |
13F
|
Company |
0.01%
|
500
|
$1,835 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0%
|
29
|
$106 | — | 30 Sep 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
—
mixed-class rows
|
62
mixed-class rows
|
$50 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
4
|
$15 | — | 30 Sep 2025 | |
| DANSKE BANK A/S |
13F
|
Company |
0%
|
1
|
$4 | — | 30 Sep 2025 | |
| Bruce J. McCreedy Jr. |
3/4/5
|
Director |
—
class O/S missing
|
20,500
|
— | — | 20 Feb 2024 | |
| David J. Arthur |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
20,500
|
— | — | 11 Apr 2024 | |
| Jonathan I. Lieber |
3/4/5
|
Director |
—
class O/S missing
|
20,500
|
— | — | 20 Feb 2024 | |
| Paul Lammers |
3/4/5
|
Director |
—
class O/S missing
|
20,500
|
— | — | 20 Feb 2024 | |
| Tess Burleson |
3/4/5
|
Director |
—
class O/S missing
|
20,500
|
— | — | 20 Feb 2024 | |
| William K. McVicar |
3/4/5
|
Director |
—
class O/S missing
|
20,500
|
— | — | 20 Feb 2024 |
Institutional Holders of Decoy Therapeutics Inc. - Common Stock, $0.0001 par value per share (DCOY) as of Q4 2025
As of 31 Dec 2025,
Decoy Therapeutics Inc. - Common Stock, $0.0001 par value per share (DCOY) was held by
9 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
79,250 shares.
The largest 9 holders included
Warberg Asset Management LLC, StoneX Group Inc., XTX Topco Ltd, GEODE CAPITAL MANAGEMENT, LLC, UBS Group AG, Tower Research Capital LLC (TRC), BANK OF AMERICA CORP /DE/, OSAIC HOLDINGS, INC., and DANSKE BANK A/S.
This page lists
9
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
5
Q4 2025 holders
9
Holder diff
4
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.